<DOC>
	<DOCNO>NCT01001013</DOCNO>
	<brief_summary>The objective study investigate drug interaction LC15-0444 pioglitazone compare safety , tolerability pharmacokinetics LC15-0444 pioglitazone administer concomitantly alone healthy male subject .</brief_summary>
	<brief_title>Pharmacokinetic Drug Interaction Between LC15-0444 Pioglitazone After Oral Administration Healthy Male Subjects</brief_title>
	<detailed_description>This study randomize , open-label , three-treatment , three-period , three-sequence crossover design healthy volunteer evaluate tolerability , safety pharmacokinetics multiple administration LC15-0444 pioglitazone concomitantly alone . Eligibility participation study determine demographic information , medical history , physical examination , electrocardiogram ( ECG ) clinical laboratory test within 3 week ( -21 ~ -2 ) drug administration ( 1 ) . Eligible subject randomize one three sequence group . According characteristic anti-diabetic drug , expect administer anti-diabetic drug . Therefore , Drug-Drug Interaction Pioglitazone identify trial .</detailed_description>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Healthy male subject age 20 45 year screen 2 . Subjects Body Mass Index ( BMI ) 18.0 ( inclusive ) 27.0 kg/m2 ( exclusive ) ; total body weight 55 kg ( inclusive ) 90 kg ( exclusive ) . BMI ( kg/m2 ) = body weight ( kg ) / { height ( ) } 2 . 3 . Subjects fast plasma glucose ( FPG ) level 70125 mg/dL ( inclusive ) time screen . 4 . Evidence personally sign date informed consent document indicate subject inform pertinent aspects trial . 1 . Subjects evidence history clinically significant hepatic ( include carrier viral hepatitis ) , renal , neurologic ( mood disorder , obsessivecompulsive disorder etc . ) , immunologic , pulmonary , endocrine , hematological , neoplastic , cardiovascular psychiatric disease . 2 . Subjects evidence history gastrointestinal disease ( Crohn 's disease , ulcer , acute chronic pancreatitis etc . ) surgery ( except appendectomy herniotomy ) possibly affect drug absorption . 3 . Subjects history hypersensitivity include drug allergy ( cause aspirin , antibiotic , etc . ) , history clinically significant hypersensitivity . 4 . Subjects meet follow criterion time screen examination ; Serum AST ( SGOT ) ALT ( SGPT ) : &gt; 1.5 time upper normal limit Creatinine clearance calculate CockcroftGault equation &lt; 80 mL/min Clinical significant abnormality ECG include 12lead ECG demonstrate QTc &gt; 450 msec screen rhythm except sinus rhythm 5 . Subjects show follow vital sign result sit position rest 3 min ; SBP : ≤ 100 mmHg ≥ 150 mmHg DBP : ≤ 60 mmHg ≥ 95 mmHg 6 . Subjects history drug abuse positive urine result drug screen drug abuse cotinine . 7 . Subjects take prescribed medicine herbal medicine within 2 week first administration investigational product , nonprescribed medicine vitamin supplement within 1 week first administration investigational product . ( If condition satisfy , subject may eligible trial investigator 's judgment . ) 8 . Subjects participate clinical trial within 2 month first administration investigational product . 9 . Subjects donate unit blood within 2 month blood component within 1 month first administration investigational product . 10 . Subjects consume 21 unit alcohol per week ( 1 unit = 10 g pure alcohol ) unable abstain drink throughout trial . 11 . Smokers ( except quit smoking least 3 month first administration investigational product ) 12 . Subjects take caffeinecontaining grapefruitcontaining product within 3 day first administration investigational product .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>